BENEFITS OF ANDROGEN REPLACEMENT THERAPY AND AUDIO-VISUAL CORRECTION INCLUSION IN THE PREVENTION OF PREMATURE AGING

2020 ◽  
pp. 385-390
Author(s):  
Г. А. Прощай ◽  
Е. Ю. Загарских ◽  
С. А. Парцерняк ◽  
А. С. Парцерняк
Keyword(s):  
Diabetes Mellitus ◽  
Standard Therapy ◽  
Depressive Disorders ◽  
Glycated Hemoglobin ◽  
Premature Aging ◽  
Homa Index ◽  
Androgen Deficiency ◽  
Laboratory Examination ◽  
Testosterone Undecanoate ◽  
Visual Correction

С возрастом происходят изменения в обмене веществ, репродуктивной и нервной системах, имеющие системный и взаимосвязанный характер. Цель работы - демонстрация эффективности аудиовизуальной коррекции и терапии препаратами тестостерона в дополнение к стандартной терапии полиморбидной патологии. Обследованы 89 мужчин 35-55 лет с сахарным диабетом 2-го типа, полиморбидной сердечно-сосудистой патологией, избытком массы тела или ожирением, андрогенным дефицитом и тревожно-депрессивными расстройствами, которых разделили на три группы в зависимости от проводимого лечения: 1-я - стандартная терапия и эсциталопрам/тофизопам; 2-я - стандартная терапия + аудиовизуальная коррекция; 3-я - стандартная терапия + аудиовизуальная коррекция + тестостерон ундеканоат. До начала лечения и через 9 мес после всем пациентам проведено лабораторное обследование. Выраженность андрогенодефицита и эректильной дисфункции определяли с помощью опросников МИЭФ-5 и Шкалы старения мужчины AMS. Выявлено снижение уровня тестостерона, признаки эректильной дисфункции и симптомы андрогенодефицита от умеренной степени выраженности до выраженной, повышение атерогенных и снижение антиатерогенных липопротеидов, повышение уровня глюкозы, гликированного гемоглобина, инсулина, индекса HOMA . После лечения выявлено более значимое улучшение липидного профиля при использовании аудиовизуальной коррекции, а аудиовизуальная коррекция и терапия андрогенами способствовали улучшению показателей эректильной функции и снижению степени выраженности симптомов старения у мужчин. There are changes in the metabolism, reproductive and nervous systems with ageing, which have a systemic and interrelated nature. The purpose of this work was to demonstrate the effectiveness of audiovisual correction and therapy with testosterone drugs in addition to the standard therapy in patients with polymorbid pathology. 89 men aged 35-55 years old with diabetes mellitus, polymorbid cardiovascular disease, obesity, anxiety and depressive disorders were examined. They were divided into 3 groups depending on the treatment: the 1 - standard therapy and escitalopram / tofisopam; the 2 - standard therapy + audiovisual correction; the 3 - standard therapy + audiovisual correction + testosterone undecanoate. Laboratory examination was carried out in all patients before the start of treatment and 9 months after the treatment. The severity of androgen deficiency was determined using IIEF-5 questionnaire and the AMS male aging scale. In was shown a decrease in testosterone levels, signs of erectile dysfunction and symptoms of moderate to severe androgen deficiency, increased proatherogenic and decreased antiatherogenic lipoproteins, increased glucose, glycated hemoglobin, insulin, HOMA index in our study. In group of audiovisual correction we saw a more significant improvement in the lipid profile after treatment. Audiovisual correction and androgen therapy contributed to the improvement of erectile function indices and a decrease in the severity of the symptoms of ageing in men.

scholarly journals Depressive disorders in patients with diabetes mellitus. The effect of sedariston phytopreparation on carbohydrate metabolism and psycho-emotional state of patients with anxiety-depressive syndrome

2021 ◽  
Vol 17 (7) ◽  
pp. 562-569
Author(s):  
S.M. Tkach ◽  
T.L. Miliutina
Keyword(s):  
Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Depressive Disorders ◽  
Emotional State ◽  
Glycated Hemoglobin ◽  
Depressive Syndrome ◽  
Control Group ◽  
Patients With Diabetes ◽  
Reactive Anxiety ◽  
Personal Anxiety

Background. Depressive disorders are quite common in patients with diabetes mellitus (DM). Depression is associated with worsening glycemic control. Attempts to improve it through the use of synthetic antidepressants in complex therapy have had mixed results. The study was aimed to evaluate the prevalence of depressive disorders in patients with diabetes mellitus treated in the endocrinology department and to evaluate the effect of combined herbal medicine Sedariston containing standardized extracts of Hypericum perforatum (100 mg) and Valeriana (50 mg) (Esparma GmbH, Germany) on carbohydrate metabolism and psycho-emotional state of diabetic patients with the anxiety-depressive syndrome. Materials and methods. The study included 122 patients with type 1 and 2 DM, 103 women and 19 men, aged 18 to 75 years. Thirty-three of them with anxiety-depressive syndrome participated in a 3-month study, 16 of which additionally received Sedariston 2 capsules twice a day for 2 months. Prior to, as well as 2 weeks, 1, 2, 3 months from the beginning of the observation, the psycho-emotional state was assessed with a determination of the severity of the depressive syndrome on the PHQ-9, Beck scales, as well as the state of personal and reactive anxiety on the Spielberger-Hanin’s scales. Glycated hemoglobin was determined before and 3 months after the start of monitoring. All patients received insulin therapy and/or hypoglycemic oral medications at constant doses during the observation. Results. Depressive disorders were identified in 80.3 and 67.2 %, respectively, according to the PHQ-9 and Beck scales. Most patients experienced mild and moderate depression. High personal anxiety was found in 66.4 %, high reactive anxiety in 50.8 % of patients. Patients in the Sedariston basic group reported significant improvement in depressive symptomatology with a decrease in PHQ-9 scores from 13.7 ± 1.6 to 9.3 ± 1.4 (p < 0.05) after 1 month of treatment, and on the Beck’s scale from 23.9 ± 1.8 to 18.2 ± 1.9 points (p < 0.05) after 2 months of treatment, in contrast to patients in the control group without Sedariston: 11.9 ± 1.2 and 10.8 ± 1.1 points (p > 0.1) on the PHQ-9 scale and 19.7 ± 1.7 and 18.9 ± 2.3 points (p > 0.1) on the Beck’s scale, respectively. The achieved improvement of the psycho-emotional state of patients after the end of treatment with Sedariston was maintained after 3 months from the beginning of monitoring: 7.1 ± 1.3 points on the PHQ-9 scale and 16.1 ± 2.1 points on the Beck’s scale (p < 0.01). After 2 months of Sedariston therapy in the group of patients with the anxiety-depressive syndrome, unlike the patients of the control group, personal anxiety decreased from 59.5 ± 2.2 to 53.5 ± 1.9 points on the Spielberger-Hanin’s scale (p < 0.05), in patients with high reactive anxiety, after 2 months of treatment significantly decreased its level from 57.4 ± 2.5 to 49.3 ± 2.7 points and remained so until the end of observation. Against the background of the positive dynamics of depressive symptoms in patients receiving Sedariston, a significant decrease in glycated hemoglobin occurred 3 months after the start of therapy: from 9.4 ± 0.5 to 8.1 ± 0.2 % (p < 0.05), unlike the patients of the control group. Conclusions. An anxiety-depressive syndrome is defined in 63.1 % of patients of the diabetology department, with depressive disorders mainly of mild and moderate severity, high personality and reactive anxiety, and 19.7 % of patients experienced a depressive syndrome without disturbance of anxiety, which indicates their diagnosis and conducting appropriate treatment. The combined phytopreparation Sedariston in the complex therapy of patients with diabetes mellitus, against the backdrop of the positive and long-lasting effect on anxiety-depressive symptoms, contributes to the improvement of carbohydrate metabolism, with a decrease of 1.3 % of glycated hemoglobin in 3 months. This indicates that Sedariston may be used not only for the treatment of anxiety-depressive syndrome but also to improve carbohydrate metabolism in patients with DM.

scholarly journals Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy

Diseases ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 16
Author(s):  
Giulia Casadei ◽  
Marta Filippini ◽  
Lorenzo Brognara
Keyword(s):  
Diabetes Mellitus ◽  
Peripheral Neuropathy ◽  
Diabetic Foot ◽  
Glycated Hemoglobin ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Glycemic Variability ◽  
Future Research ◽  
Patients With Diabetes ◽  
Axonal Dysfunction ◽  
Biomarker Research

Background: Diabetic peripheral neuropathy (DPN) is known to predict foot ulceration, lower-extremity amputation and mortality. Patients with diabetes mellitus have a predisposition toward developing chronic inflammatory demyelinating polyneuropathy, and this may also facilitate the formation of diabetic foot and cutaneous impairment, which are considered one of the most serious impairments of diabetes mellitus, with a prevalence of 4–10% in this population. Biomarkers research provides opportunities for the early diagnosis of these complications for specific treatments useful to prevent amputation and, therefore, physical inability and mental disturbance. The recent literature has suggested that glycemic levels may be a novel factor in the pathogenesis of diabetic foot complications and is an important mediator of axonal dysfunction. The aim of this systematic literary review is to determine whether hemoglobin A1c (HbA1c) is a positive predictor for diabetic foot peripheral neuropathy and its complications, such as foot cutaneous impairments. There is a lack of consensus regarding the effect of glycemic variability on diabetic foot peripheral neuropathy, unlike other complications such as retinopathy, nephropathy or micro/macrovascular pathology. Methods: Relevant articles were searched in the Medline database using PubMed and Scopus and relevant keywords. The primary search terms used were “glycated hemoglobin” OR “HbA1c” AND “diabetic neuropathies” AND “Foot”. Results: A number of articles (336) were initially identified while searching the scientific literature regarding this topic, and 32 articles were selected and included in this review. Conclusions: This review highlights the role of HbA1c in diabetic foot peripheral neuropathy. Biomarkers play an important role in the decision-making process, and HbA1c levels are extensively used for diabetic foot clinical outcomes and settings, but biomarker research in diabetic foot peripheral neuropathy is in its infancy and will require careful attention to a number of factors and associations, since the consequences of DPN also include neurological alterations. HbA1c is an accurate and easy-to-administer test and can be an effective biomarker in establishing the diagnosis of diabetes, but future research should focus on standardizing the HbA1c level and selecting which DPN value and its correlated complications, such as foot cutaneous impairments, are the most informative.

Relationship between glycated hemoglobin and glucose concentrations in the adult Galician population: selection of optimal glycated hemoglobin cut-off points as a diagnostic tool of diabetes mellitus

2012 ◽  
Vol 59 (8) ◽  
pp. 496-504 ◽  
Author(s):  
Manuel Antonio Botana López ◽  
Mónica López Ratón ◽  
María Ausencia Tomé ◽  
Alexis Fernández Mariño ◽  
José Antonio Mato Mato ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diagnostic Tool ◽  
Glycated Hemoglobin ◽  
Population Selection ◽  
Selection Of

Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus?

2007 ◽  
Vol 12 (3) ◽  
pp. 133-139 ◽  
Author(s):  
Baris Afsar ◽  
Siren Sezer ◽  
Rengin Elsurer ◽  
Fatma Nurhan Ozdemir
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Homa Index ◽  
Newly Diagnosed

scholarly journals Utility of Glycated Hemoglobin in Diagnosing Type 2 Diabetes Mellitus: A Community-Based Study

2010 ◽  
Vol 95 (6) ◽  
pp. 2832-2835 ◽  
Author(s):  
Padala Ravi Kumar ◽  
Anil Bhansali ◽  
Muthuswamy Ravikiran ◽  
Shobhit Bhansali ◽  
Pinaki Dutta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diagnostic Test ◽  
Sensitivity And Specificity ◽  
Predictive Value ◽  
Hba1c Level ◽  
Glycated Hemoglobin ◽  
World Health ◽  
Oral Glucose ◽  
Community Based ◽  
Cut Point

Abstract Context: Although glycated hemoglobin (HbA1c) has recently been incorporated as a diagnostic test by the American Diabetes Association, its validity needs to be established in Asian Indians in a community setting. Objective: The objective of the study was to assess the validity of HbA1c as a screening and diagnostic test in individuals with newly detected diabetes mellitus. Design and Setting: Community based randomized cross sectional study in urban Chandigarh, a city in north India, from April 2008 to August 2009. Subjects: Subjects included 1972 subjects aged 20 yr or older. Intervention: Intervention included an oral glucose tolerance test and glycated hemoglobin in all the subjects. Main Outcome Measures: Utility of HbA1c as a diagnostic method in newly detected diabetes mellitus subjects was evaluated. Results: Using World Health Organization criteria for diagnosis of diabetes mellitus, 134 (6.7%) had newly detected diabetes mellitus, 192 (9.7%) known diabetes mellitus, 329 (16.6%) prediabetes, and 1317 (69.4%) were normal of 1972 people screened. Using only the ADA criteria, 38% people were underdiagnosed. An HbA1c level of 6.1% had an optimal sensitivity and specificity of 81% for diagnosing diabetes. A HbA1c level of 6.5% (±2 sd) and 7% (±2.7 sd) had sensitivity and specificity of 65 and 88% and 42 and 92%, respectively, with corresponding positive predictive value and negative predictive value of 75.2 and 96.5% and 90.4and 94.4%, respectively, for diagnosis of newly detected diabetes mellitus. Conclusion: A HbA1c cut point of 6.1% has an optimal sensitivity and specificity of 81% and can be used as a screening test, and a cut point of 6.5% has optimal specificity of 88% for diagnosis of diabetes.

The Association of Red Cell Distribution Width with Glycated Hemoglobin among Healthy Adults without Diabetes Mellitus

Cardiology ◽  
2012 ◽  
Vol 122 (2) ◽  
pp. 129-132 ◽  
Author(s):  
Vikas Veeranna ◽  
Sandip K. Zalawadiya ◽  
Sidakpal S. Panaich ◽  
Krithi Ramesh ◽  
Luis Afonso
Keyword(s):  
Diabetes Mellitus ◽  
Glycated Hemoglobin ◽  
Healthy Adults ◽  
Red Cell Distribution Width ◽  
Red Cell ◽  
Cell Distribution ◽  
Distribution Width
Sign in / Sign up

Export Citation Format

Share Document